768 Peripheral Pharmacodynamic (PD) Effects of Ociperlimab (OCI) in Combination with Tislelizumab (TIS) in Patients with Advanced Solid Tumors: AdvanTIG-105 Phase 1 Dose-Escalation Study
Regular and Young Investigator Award Abstracts（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined